Browse by category

Detailed results from the phase 3 SURMOUNT-3 clinical trial evaluating tirzepatide in adults with obesity or overweight with...

A new meta-analysis combining 22 studies shows that tirzepatide is superior to semaglutide for both control of blood sugar and in terms...

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended tirzepatide (Mounjaro, developed by Eli Lilly) in...

Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...

Tirzepatide (Mounjaro) has a unique ability to activate two different mechanisms the body uses to control insulin secretion and energy...

Seventy-two week outcomes from the SURMOUNT-2 trial has revealed that tirzepatide (10mg and 15mg) achieved superior weight loss compared...

Eli Lilly and Company has registered its intent to carry out a Phase 3b clinical trial that will see the company’s tirzepatide (Mounjaro)...

Several anti-obesity medications could be manufactured and profitability sold worldwide at far lower estimated lower prices compared to...

An analysis of the SURPASS-4 trial has reported that type 2 diabetics with high cardiovascular risk who took resulted in a slowed the...